Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept 8 mg in Resistant Diabetic Macular Edema
NCT06879301Phase 1Completed
- Sponsor
- Tanta University
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Tanta University. Primary endpoint: Best corrected visual acuity at 1 month. Started Mar 2025; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06879301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879301.